【一期一会】美迪西11月直播，沙龙，行业展会大放送，期待与你全球相会

Tips

十一月美迪西将主办2 场线上直播，同时参与5 场海内外行业会议，期待与各位业内同仁交流分享药物研发新趋势。

15^th World ADC San Diego 2024

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. 15^th World ADC San Diego 2024 is only one week to go!

We are excited to invite you to visit us at Medicilon Booth #512. Our Science and Business teams are looking forward to meeting you.

SITC 2024

Ready to Meet Medicilon at SITC's 39^th Annual Meeting & Pre-Conference Programs (SITC2024)? 

We are happy to meet you in person to discuss how our services and capabilities can support your research and expedite your drug discovery and development activities. Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers. Medicilon has built a one-stop service platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

首届创新药研发和多维度治疗前沿峰会

2024年11月9-10日，由四川大学华西医院、中国细胞生物学学会主办，中国免疫学会、四川大学华西医院生物治疗全国重点实验室、四川省国际医学交流促进会、四川大学华西医院免疫炎症研究院联合主办，苏州盛杰、GenEros Bio Pharma、健桥海承办的“首届创新药研发和多维度治疗前沿峰会暨JAK-STAT信号通路发现30周年庆典”将在成都举办。

美迪西创始人&CEO陈春麟博士将分享“Efficacy and Preclinical Research on JAK3 Inhibitor JANEX-1 for Treatment of Allergic Reaction and Asthma”！

美迪西团队将在1号展位全程设展！

第十七届百世化学制药国际大会暨展览会

2024年11月13-14日，由百世传媒主办，广东医谷、广东省药学会制药工程专业委员会、广东省生物医药创新技术协会、全球健康药物研发中心、聊城大学生物制药研究院等联合主办的“CIS-Asia 2024 第十七届百世化学制药国际大会暨展览会”将在广州举办。

美迪西化学部研发副总裁李志刚博士将分享“以靶向EGFR的PROTAC药物研发为例的X-TAC研发思考”！

美迪西团队将在25号展位全程设展！

ACT 2024

American College of Toxicology (ACT) 2024 kicks off on November 17 2024 at JW Marriott Austin, Austin, Texas. Maybe we can work together and Medicilon can be a great partner! Come and chat with our American team at booth #117! Medicilon offers comprehensive toxicology study services designed to assess the safety profile and potential risks of pharmaceutical compounds. Our expert team collaborates closely with clients to tailor studies according to regulatory requirements and project-specific needs. Our state-of-the-art facilities, advanced platform, experienced scientists, and commitment to quality ensure that clients receive high quality, reliable, and regulatory-compliant GLP toxicology data to support the development of safe and effective pharmaceutical products. Medicilon has been at the forefront of pharmaceutical R&D for over 20 years. We have supported more than 2,000 global clients and have contributed to the IND approval of more than 490 drugs.

marketing@medicilon.com.cn
媒体与会务请联系
美迪西市场部微信或邮箱